Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Equivalents (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Cash & Equivalents readings, the most recent being $466.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 13.35% year-over-year to $466.2 million, compared with a TTM value of $466.2 million through Dec 2025, up 13.35%, and an annual FY2025 reading of $466.2 million, up 13.35% over the prior year.
  • Cash & Equivalents hit $466.2 million in Q4 2025 for Apellis Pharmaceuticals, down from $479.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $765.1 million in Q1 2023, with the low at $265.4 million in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $431.9 million (2023), compared with a mean of $459.3 million.
  • The sharpest move saw Cash & Equivalents surged 138.65% in 2022, then tumbled 57.4% in 2024.
  • Year by year, Cash & Equivalents stood at $640.2 million in 2021, then decreased by 13.81% to $551.8 million in 2022, then tumbled by 36.36% to $351.2 million in 2023, then grew by 17.11% to $411.3 million in 2024, then rose by 13.35% to $466.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $466.2 million, $479.2 million, and $370.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.